Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes
ICD-10 C77.2 is a billable code used to indicate a diagnosis of secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes.
C77.2 refers to secondary malignant neoplasms that have metastasized to the intra-abdominal lymph nodes from a primary cancer site, which may be unknown. This condition indicates that cancer cells have spread from their original site to the lymph nodes located within the abdominal cavity. The presence of malignant cells in these lymph nodes often signifies advanced disease and can complicate treatment options. Patients may present with symptoms such as abdominal pain, weight loss, and lymphadenopathy. The staging of this condition is crucial, as it helps determine the extent of disease spread and guides treatment decisions. In cases where the primary tumor is not identified, further diagnostic workup may be necessary to locate the source of metastasis. Palliative care considerations are essential for managing symptoms and improving quality of life, especially in advanced stages where curative treatment may not be feasible. The management of patients with C77.2 often involves a multidisciplinary approach, including oncologists, palliative care specialists, and primary care providers.
Clear documentation of the primary cancer site, staging, and treatment plans.
Patients with known primary cancers presenting with abdominal lymphadenopathy.
Ensure accurate staging and documentation of metastatic disease.
Detailed symptom management plans and goals of care discussions.
Patients with advanced cancer requiring symptom relief.
Focus on quality of life and symptom management documentation.
Used when a biopsy is performed to confirm malignancy in lymph nodes.
Pathology report must be included in the medical record.
Oncologists should ensure that biopsy results are clearly documented.
Coding C77.2 accurately reflects the presence of secondary malignant neoplasms in intra-abdominal lymph nodes, which is crucial for treatment planning and understanding the extent of disease.
